, Volume 35, Issue 4, pp 1402–1410 | Cite as

The Efficiency of Proanthocyanidin in an Experimental Pulmonary Fibrosis Model: Comparison with Taurine

  • Yetkin Agackiran
  • Husamettin Gul
  • Ersin Gunay
  • Nalan Akyurek
  • Leyla Memis
  • Sibel Gunay
  • Yusuf Sinan Sirin
  • Tayfun Ide


Pulmonary fibrosis (PF) is a progressive fatal disorder. Bleomycin (BLM) is a widely used chemotherapeutic agent causing PF. Numerous agents have been investigated to prevent the progression of PF so far, but there is still a need to find more efficacious agents. Proanthocyanidin (PA) is a strong antioxidant, the main ingredient of grape seed extract. Since PA is ready for use in practice, we aimed to compare the preventive effect of PA in comparison with taurine (Tau) in BLM-induced PF. Forty Wistar male albino rats were used in the study and were divided into four groups: group 1, control; group 2, BLM-induced PF group; group 3, BLM-induced PF and treated with PA group; and group 4, BLM-induced PF and treated with Tau group. Treatments were begun 10 days before and continued 21 days after BLM injection. PA and Tau effectively inhibited inflammation, edema, severity of fibrosis, fibrosis extension, inflammatory cell accumulation, iNOS staining, and hydroxyproline level as well (p < 0.05). Total histological scores of the PA group were similar to the control group; Tau was significantly higher than the control group but lower than the BLM group (p < 0.05). We believe that PA could be a new treatment choice for PF, but further studies need to be conducted to verify the findings of the current study.


bleomycin proanthocyanidin pulmonary fibrosis iNOS hydroxyproline inflammation 



The authors would like to thank Patricia B. Upton for the critical reading of the manuscript.

Conflict of Interest

The authors declare that there are no conflicts of interest.


  1. 1.
    Panos, R.J., R.L. Mortenson, S.A. Niccoli, and T.E. King Jr. 1990. Clinical deterioration in patients with idiopathic pulmonary fibrosis: Causes and assessment. American Journal of Medicine 88: 396–404.PubMedCrossRefGoogle Scholar
  2. 2.
    Kelley, J. 1990. Cytokines of the lung. American Review of Respiratory Disease 141: 765–788.PubMedCrossRefGoogle Scholar
  3. 3.
    Manoury, B., S. Nenan, O. Leclerc, I. Guenon, E. Boichot, J.M. Planquois, et al. 2005. The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis. Respiratory Research 6: 11.PubMedCrossRefGoogle Scholar
  4. 4.
    Morcillo, E.J., J. Estrela, and J. Cortijo. 1999. Oxidative stress and pulmonary inflammation: Pharmacological intervention with antioxidants. Pharmacological Research 40: 393–404.PubMedCrossRefGoogle Scholar
  5. 5.
    Nakatani-Okuda, A., H. Ueda, S. Kashiwamura, A. Sekiyama, A. Kubota, Y. Fujita, et al. 2005. Protection against bleomycin-induced lung injury by IL-18 in mice. American Journal of Physiology. Lung Cellular and Molecular Physiology 289: L280–L287.PubMedCrossRefGoogle Scholar
  6. 6.
    Caspary, W.J., D.A. Lanzo, and C. Niziak. 1982. Effect of deoxyribonucleic acid on the production of reduced oxygen by bleomycin and iron. Biochemistry 21: 334–338.PubMedCrossRefGoogle Scholar
  7. 7.
    Moeller, A., K. Ask, D. Warburton, J. Gauldie, and M. Kolb. 2008. The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis? The International Journal of Biochemistry & Cell Biology 40: 362–382.CrossRefGoogle Scholar
  8. 8.
    Bentivegna, S.S., and K.M. Whitney. 2002. Subchronic 3-month oral toxicity study of grape seed and grape skin extracts. Food and Chemical Toxicology 40: 1731–1743.PubMedCrossRefGoogle Scholar
  9. 9.
    Shao, Z.H., L.B. Becker, T.L. Vanden Hoek, P.T. Schumacker, C.Q. Li, D. Zhao, et al. 2003. Grape seed proanthocyanidin extract attenuates oxidant injury in cardiomyocytes. Pharmacological Research 47: 463–469.PubMedCrossRefGoogle Scholar
  10. 10.
    Yanarates, O., A. Guven, A. Sizlan, B. Uysal, O. Akgul, A. Atim, et al. 2008. Ameliorative effects of proanthocyanidin on renal ischemia/reperfusion injury. Renal Failure 30: 931–938.PubMedCrossRefGoogle Scholar
  11. 11.
    Eraslan, G., S. Saygi, D. Essiz, A. Aksoy, H. Gul, and E. Macit. 2007. Evaluation of aspect of some oxidative stress parameters using vitamin E, proanthocyanidin and N-acetylcysteine against exposure to cyfluthrin in mice. Pesticide Biochemistry and Physiology 88: 43–46.CrossRefGoogle Scholar
  12. 12.
    Fitzpatrick, D.F., R.C. Fleming, B. Bing, D.A. Maggi, and R.M. O'Malley. 2000. Isolation and characterization of endothelium-dependent vasorelaxing compounds from grape seeds. Journal of Agricultural and Food Chemistry 48: 6384–6390.PubMedCrossRefGoogle Scholar
  13. 13.
    Sano, T., E. Oda, T. Yamashita, A. Naemura, Y. Ijiri, J. Yamakoshi, et al. 2005. Anti-thrombotic effect of proanthocyanidin, a purified ingredient of grape seed. Thrombosis Research 115: 115–121.PubMedCrossRefGoogle Scholar
  14. 14.
    Bagchi, D., C.K. Sen, S.D. Ray, D.K. Das, M. Bagchi, H.G. Preuss, et al. 2003. Molecular mechanisms of cardioprotection by a novel grape seed proanthocyanidin extract. Mutation Research 523–524: 87–97.PubMedCrossRefGoogle Scholar
  15. 15.
    Ferguson, P.J., E.M. Kurowska, D.J. Freeman, A.F. Chambers, and J. Koropatnick. 2006. In vivo inhibition of growth of human tumor lines by flavonoid fractions from cranberry extract. Nutrition and Cancer 56: 86–94.PubMedCrossRefGoogle Scholar
  16. 16.
    Miyazaki, T., M. Karube, Y. Matsuzaki, T. Ikegami, M. Doy, N. Tanaka, et al. 2005. Taurine inhibits oxidative damage and prevents fibrosis in carbon tetrachloride-induced hepatic fibrosis. Journal of Hepatology 43: 117–125.PubMedCrossRefGoogle Scholar
  17. 17.
    Schuller-Levis, G., R.E. Gordon, C. Wang, S.Y. Park, and E. Park. 2009. Protection of bleomycin-induced fibrosis and inflammation by taurine. International Immunopharmacology 9: 971–977.PubMedCrossRefGoogle Scholar
  18. 18.
    Yucel, O., Z.I. Kunak, E. Macit, A. Gunal, A. Gozubuyuk, H. Gul, et al. 2008. Protective efficacy of taurine against pulmonary edema progression: Experimental study. Journal of Cardiothoracic Surgery 3: 57.PubMedCrossRefGoogle Scholar
  19. 19.
    Chaudhary, N.I., A. Schnapp, and J.E. Park. 2006. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. American Journal of Respiratory and Critical Care Medicine 173: 769–776.PubMedCrossRefGoogle Scholar
  20. 20.
    Cortijo, J., M. Cerda-Nicolas, A. Serrano, G. Bioque, J.M. Estrela, F. Santangelo, et al. 2001. Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats. European Respiratory Journal 17: 1228–1235.PubMedCrossRefGoogle Scholar
  21. 21.
    Hsu, S.M., L. Raine, and H. Fanger. 1981. Use of avidin–biotin–peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. Journal of Histochemistry and Cytochemistry 29: 577–580.PubMedCrossRefGoogle Scholar
  22. 22.
    Woessner Jr., J.F. 1961. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Archives of Biochemistry and Biophysics 93: 440–447.PubMedCrossRefGoogle Scholar
  23. 23.
    Demedts, M., A.U. Wells, J.M. Antó, U. Costabel, R. Hubbard, P. Cullinan, H. Slabbynck, G. Rizzato, V. Poletti, E.K. Verbeken, M.J. Thomeer, J. Kokkarinen, J.C. Dalphin, and A.N. Taylor. 2001. Interstitial lung diseases: An epidemiological overview. The European Respiratory Journal. Supplement 32: 2s–16s.PubMedGoogle Scholar
  24. 24.
    Chen, F., L. Gong, L. Zhang, H. Wang, X. Qi, X. Wu, et al. 2006. Short courses of low dose dexamethasone delay bleomycin-induced lung fibrosis in rats. European Journal of Pharmacology 536: 287–295.PubMedCrossRefGoogle Scholar
  25. 25.
    Hagiwara, S.I., Y. Ishii, and S. Kitamura. 2000. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. American Journal of Respiratory and Critical Care Medicine 162: 225–231.PubMedGoogle Scholar
  26. 26.
    Bouros, D., K.M. Antoniou, A. Tzouvelekis, and N.M. Siafakas. 2006. Interferon-gamma 1b for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Biological Therapy 6: 1051–1060.PubMedCrossRefGoogle Scholar
  27. 27.
    Wang, Q., D.M. Hyde, P.J. Gotwals, and S.N. Giri. 2002. Effects of delayed treatment with transforming growth factor-beta soluble receptor in a three-dose bleomycin model of lung fibrosis in hamsters. Experimental Lung Research 28: 405–417.PubMedCrossRefGoogle Scholar
  28. 28.
    Daba, M.H., A.A. Abdel-Aziz, A.M. Moustafa, A.A. Al-Majed, O.A. Al-Shabanah, and H.A. El-Kashef. 2002. Effects of l-carnitine and ginkgo biloba extract (EG b 761) in experimental bleomycin-induced lung fibrosis. Pharmacological Research 45: 461–467.PubMedCrossRefGoogle Scholar
  29. 29.
    Jakubzick, C., E.S. Choi, B.H. Joshi, M.P. Keane, S.L. Kunkel, R.K. Puri, et al. 2003. Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells. Journal of Immunology 171: 2684–2693.Google Scholar
  30. 30.
    Wang, Q., M.A. Hollinger, and S.N. Giri. 1992. Attenuation of amiodarone-induced lung fibrosis and phospholipidosis in hamsters by taurine and/or niacin treatment. Journal of Pharmacology and Experimental Therapeutics 262: 127–132.PubMedGoogle Scholar
  31. 31.
    Blaisdell, R.J., and S.N. Giri. 1995. Mechanism of antifibrotic effect of taurine and niacin in the multidose bleomycin-hamster model of lung fibrosis: Inhibition of lysyl oxidase and collagenase. Journal of Biochemical Toxicology 10: 203–210.PubMedCrossRefGoogle Scholar
  32. 32.
    Schuller-Levis, G.B., R.E. Gordon, E. Park, K.J. Pendino, and D.L. Laskin. 1995. Taurine protects rat bronchioles from acute ozone-induced lung inflammation and hyperplasia. Experimental Lung Research 21: 877–888.PubMedCrossRefGoogle Scholar
  33. 33.
    Gurujeyalakshmi, G., Y. Wang, and S.N. Giri. 2000. Suppression of bleomycin-induced nitric oxide production in mice by taurine and niacin. Nitric Oxide 4: 399–411.PubMedCrossRefGoogle Scholar
  34. 34.
    Yildirim, Z., N. Kilic, C. Ozer, A. Babul, G. Take, and D. Erdogan. 2007. Effects of taurine in cellular responses to oxidative stress in young and middle-aged rat liver. Annals of the New York Academy of Sciences 1100: 553–561.PubMedCrossRefGoogle Scholar
  35. 35.
    Ekremoglu, M., N. Turkozkan, H. Erdamar, Y. Kurt, and H. Yaman. 2007. Protective effect of taurine on respiratory burst activity of polymorphonuclear leukocytes in endotoxemia. Amino Acids 32: 413–417.PubMedCrossRefGoogle Scholar
  36. 36.
    Guz, G., E. Oz, N. Lortlar, N.N. Ulusu, N. Nurlu, B. Demirogullari, et al. 2007. The effect of taurine on renal ischemia/reperfusion injury. Amino Acids 32: 405–411.PubMedCrossRefGoogle Scholar
  37. 37.
    Gurujeyalakshmi, G., Y. Wang, and S.N. Giri. 2000. Taurine and niacin block lung injury and fibrosis by down-regulating bleomycin-induced activation of transcription nuclear factor-kappaB in mice. Journal of Pharmacology and Experimental Therapeutics 293: 82–90.PubMedGoogle Scholar
  38. 38.
    Nobili, S., D. Lippi, E. Witort, M. Donnini, L. Bausi, E. Mini, et al. 2009. Natural compounds for cancer treatment and prevention. Pharmacological Research 59: 365–378.PubMedCrossRefGoogle Scholar
  39. 39.
    Salah, N., N.J. Miller, G. Paganga, L. Tijburg, G.P. Bolwell, and C. Rice-Evans. 1995. Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Archives of Biochemistry and Biophysics 322: 339–346.PubMedCrossRefGoogle Scholar
  40. 40.
    Rice-Evans, C.A., N.J. Miller, and G. Paganga. 1996. Structure–antioxidant activity relationships of flavonoids and phenolic acids. Free Radical Biology & Medicine 20: 933–956.CrossRefGoogle Scholar
  41. 41.
    Phuwapraisirisan, P., P. Sowanthip, D.H. Miles, and S. Tip-pyang. 2006. Reactive radical scavenging and xanthine oxidase inhibition of proanthocyanidins from Carallia brachiata. Phytotherapy Research 20: 458–461.PubMedCrossRefGoogle Scholar
  42. 42.
    Bagchi, D., A. Garg, R.L. Krohn, M. Bagchi, M.X. Tran, and S.J. Stohs. 1997. Oxygen free radical scavenging abilities of vitamins C and E, and a grape seed proanthocyanidin extract in vitro. Research Communications in Molecular Pathology and Pharmacology 95: 179–189.PubMedGoogle Scholar
  43. 43.
    Rodriguez, L.O., and S.M. Hecht. 1982. Iron(II)-bleomycin. Biochemical and spectral properties in the presence of radical scavengers. Biochemical and Biophysical Research Communications 104: 1470–1476.PubMedCrossRefGoogle Scholar
  44. 44.
    Aruoma, O.I., B. Sun, H. Fujii, V.S. Neergheen, T. Bahorun, K.S. Kang, et al. 2006. Low molecular proanthocyanidin dietary biofactor Oligonol: Its modulation of oxidative stress, bioefficacy, neuroprotection, food application and chemoprevention potentials. BioFactors 27: 245–265.PubMedCrossRefGoogle Scholar
  45. 45.
    Dedon, P.C., and I.H. Goldberg. 1992. Free-radical mechanisms involved in the formation of sequence-dependent bistranded DNA lesions by the antitumor antibiotics bleomycin, neocarzinostatin, and calicheamicin. Chemical Research in Toxicology 5: 311–332.PubMedCrossRefGoogle Scholar
  46. 46.
    Sheu, S.J., N.C. Liu, and J.L. Chen. 2010. Resveratrol protects human retinal pigment epithelial cells from acrolein-induced damage. Journal of Ocular Pharmacology and Therapeutics 26: 231–236.PubMedCrossRefGoogle Scholar
  47. 47.
    Chen, Z.Y., P.T. Chan, K.Y. Ho, K.P. Fung, and J. Wang. 1996. Antioxidant activity of natural flavonoids is governed by number and location of their aromatic hydroxyl groups. Chemistry and Physics of Lipids 79: 157–163.PubMedCrossRefGoogle Scholar
  48. 48.
    Quesada, I.M., J.M. Del Bas, C. Blade, A. Ardevol, M. Blay, M.J. Salvado, et al. 2007. Grape seed procyanidins inhibit the expression of metallothione in genes in human HepG2 cells. Genes and Nutrition 2: 105–109.PubMedCrossRefGoogle Scholar
  49. 49.
    Saleh, D., P.J. Barnes, and A. Giaid. 1997. Increased production of the potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 155: 1763–1769.PubMedGoogle Scholar
  50. 50.
    Kalayarasan, S., N. Sriram, and G. Sudhandiran. 2008. Diallyl sulfide attenuates bleomycin-induced pulmonary fibrosis: Critical role of iNOS, NF-kappaB, TNF-alpha and IL-1beta. Life Sciences 82: 1142–1153.PubMedCrossRefGoogle Scholar
  51. 51.
    Yildirim, Z., Y. Turkoz, M. Kotuk, F. Armutcu, A. Gurel, M. Iraz, et al. 2004. Effects of aminoguanidine and antioxidant erdosteine on bleomycin-induced lung fibrosis in rats. Nitric Oxide 11: 156–165.PubMedCrossRefGoogle Scholar
  52. 52.
    Shah, V., and P.S. Kamath. 2003. Nitric oxide in liver transplantation: Pathobiology and clinical implications. Liver Transplantation 9: 1–11.PubMedCrossRefGoogle Scholar
  53. 53.
    Germano, D., P. Blyszczuk, A. Valaperti, G. Kania, S. Dirnhofer, U. Landmesser, et al. 2009. Prominin-1/CD133+ lung epithelial progenitors protect from bleomycin-induced pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 179: 939–949.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Yetkin Agackiran
    • 1
  • Husamettin Gul
    • 2
  • Ersin Gunay
    • 3
  • Nalan Akyurek
    • 4
  • Leyla Memis
    • 4
  • Sibel Gunay
    • 5
  • Yusuf Sinan Sirin
    • 6
  • Tayfun Ide
    • 7
  1. 1.Department of PathologyAtaturk Chest Diseases and Thoracic Surgery Training and Research HospitalKeciorenTurkey
  2. 2.Department of PharmacologyGulhane Military Medical AcademyAnkaraTurkey
  3. 3.Department of Chest Diseases, School of MedicineAfyon Kocatepe UniversityAfyonkarahisarTurkey
  4. 4.Department of Pathology, Faculty of MedicineGazi UniversityAnkaraTurkey
  5. 5.Chest Diseases ClinicIgdir State HospitalIgdirTurkey
  6. 6.Department of Surgery, Faculty of Veterinary MedicineMehmet Akif Ersoy UniversityBurdurTurkey
  7. 7.Research and Developmental InstituteGulhane Military Medical AcademyAnkaraTurkey

Personalised recommendations